Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (OTCPK:FRTX)

Brickell Biotech to Participate in March Virtual Investor Conferences

GlobeNewswire February 25, 2021

Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021

GlobeNewswire February 23, 2021

Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

GlobeNewswire January 19, 2021

Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

GlobeNewswire December 7, 2020

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

GlobeNewswire November 18, 2020

Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

GlobeNewswire November 16, 2020

Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2020

Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020

GlobeNewswire October 29, 2020

Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering

GlobeNewswire October 22, 2020

Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

GlobeNewswire October 6, 2020

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical

GlobeNewswire September 25, 2020

Brickell Biotech to Participate in September Virtual Investor Conferences

GlobeNewswire September 10, 2020

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.

GlobeNewswire September 8, 2020

Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office

GlobeNewswire August 31, 2020

Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2020

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

GlobeNewswire August 3, 2020

Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

GlobeNewswire June 17, 2020

Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical

GlobeNewswire June 15, 2020

Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2020

Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020

GlobeNewswire May 4, 2020